Mounjaro vs Ozempic: Which Is Better in 2026?

Which loses more weight?

In the SURMOUNT-1 trial, tirzepatide (the active ingredient in Mounjaro) produced average body-weight reductions of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks. The STEP 1 trial of semaglutide produced an average 14.9% reduction at 68 weeks at the 2.4 mg dose used in Wegovy.

These trials were not directly head-to-head, but the reanalysis published in 2024 estimated tirzepatide delivers roughly 5 percentage points more body-weight loss on average than semaglutide. Real-world telehealth outcomes show a smaller gap — closer to 2–3 points — likely because of dose titration, adherence, and shorter treatment duration than the registered trials.

The right molecule for an individual depends on tolerance, side-effect profile, response, and cost. Many patients start on semaglutide and switch to tirzepatide if response stalls, or vice versa if side effects are intolerable.

How do the costs compare?

Brand-name Mounjaro and Ozempic both list near $1,000/month at retail pharmacies in 2026. Insurance coverage for either drug specifically for weight loss is limited because neither is FDA-approved for weight management — Mounjaro and Ozempic are diabetes drugs, while Zepbound and Wegovy are the weight-loss-approved equivalents from the same manufacturers.

Through telehealth providers using compounded equivalents, the cash-pay cost gap narrows significantly. Compounded tirzepatide typically runs $146–$385/month while compounded semaglutide runs $99–$275/month. See our cost comparison and our top-rated providers for current pricing.

Side effects and tolerability

Both drugs share GI side effects as the most common complaint — nausea, vomiting, diarrhea, constipation, and decreased appetite. Most are mild-to-moderate and resolve over the first few weeks of titration.

Tirzepatide's dual-receptor mechanism means slightly more potent appetite suppression but also a marginally higher rate of moderate GI symptoms in the trials. Patients with sensitive digestion sometimes find semaglutide easier to tolerate at equivalent weight-loss percentage points.

Both drugs carry boxed warnings for medullary thyroid carcinoma in animal studies and contraindications for personal or family history of MTC or MEN 2.